Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that on May 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to five new employees to purchase 133,750 shares under the 2023 Inducement Option Plan, as amended.

Each option has an exercise price of $8.77 (closing price on May 1, 2026) and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and applicable plan and agreement terms.

News Market Reaction – KURA

+5.47%

23 alerts

+5.47% Session close to close

+3.2% Peak in 4 hr 27 min

$836.14M Market Cap

0.5x Rel. Volume

In the May 4 session, KURA gained 5.47%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.2% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with inv...

Analysis

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with investors treating the inducement option grants as a neutral housekeeping item, with attention remaining on earlier clinical and commercial milestones. Historically, Kura’s shares often moved upward on positive data and corporate news, as seen with the +8.28% move on ccRCC results and +5.29% on prior inducement grants, suggesting that constructive sentiment had been building around the broader story.

Key Figures

Inducement options: 133,750 shares New employees: 5 employees Exercise price: $8.77 per share +5 more

8 metrics

Inducement options 133,750 shares Nonstatutory stock options granted to five new employees

New employees 5 employees Recipients of inducement option grants on May 1, 2026

Exercise price $8.77 per share Equal to KURA closing price on May 1, 2026

Vesting period 4 years Standard vesting term for these inducement stock options

Initial vesting 25% after 1 year Cliff vesting on one-year anniversary of vesting start date

Remainder vesting 36 months Remaining shares vest monthly over next 36 months

Listing rule Nasdaq Rule 5635(c)(4) Basis for inducement grants outside stockholder-approved plan

Plan year 2023 Company’s 2023 Inducement Option Plan, as amended

Historical Context

5 past events · Latest: Apr 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 17	Clinical data update	Positive	+8.3%	Preliminary ccRCC data showed strong response and disease control rates.
Apr 09	Conference presentation	Positive	+0.7%	Announcement of upcoming IKCS Europe 2026 presentation of FIT-001 data.
Mar 06	Inducement grants	Neutral	+5.3%	Inducement stock options totaling 44,700 shares granted to new employees.
Mar 05	Earnings and update	Positive	-0.5%	Fourth quarter and 2025 results with KOMZIFTI approval, revenues and cash position.
Feb 26	Earnings date notice	Neutral	+1.1%	Scheduling announcement for Q4 and full-year 2025 results call and webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent price reactions have generally aligned positively with clinical and corporate updates, including prior inducement grant news, with only one notable divergence on a major earnings/clinical update day.

Recent Company History

Over the past few months, Kura Oncology has reported several important milestones. On April 17, 2026, robust darlifarnib plus cabozantinib data in ccRCC coincided with a +8.28% move. Earlier, on April 9, the company flagged upcoming Phase 1 FIT-001 data. A prior inducement grant announcement on March 2, 2026 saw shares up 5.29%. Financial results on March 5, 2026 combined first KOMZIFTI revenues and a substantial cash balance but were followed by a modest -0.47% reaction, while the earnings-date notice in late February drew a small gain.

Key Terms

nonstatutory stock options, nasdaq listing rule 5635(c)(4)

2 terms

nonstatutory stock options financial

"granted inducement awards consisting of nonstatutory stock options to purchase 133,750 shares"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

nasdaq listing rule 5635(c)(4) regulatory

"approved the stock options as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 133,750 shares of common stock to five (5) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $8.77 per share, the closing price of the Company’s common stock on May 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

What did KURA announce on May 4, 2026 about inducement grants?

Kura granted inducement nonstatutory stock options to five new employees on May 1, 2026. According to the company, the grants total 133,750 options under the 2023 Inducement Option Plan, with terms tied to continued service and the plan's option agreement.

How many shares and what exercise price were included in KURA's May 1, 2026 grants?

The grants cover 133,750 shares with an exercise price of $8.77 per share. According to the company, $8.77 equals the closing price of KURA common stock on May 1, 2026, and options vest over a four-year schedule.

What is the vesting schedule for the KURA inducement stock options (Nasdaq: KURA)?

The options vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months. According to the company, vesting is subject to each new employee's continued service through applicable vesting dates.

Under which plan were KURA's inducement options granted and why?

The options were granted under the company's 2023 Inducement Option Plan, as amended. According to the company, the Compensation Committee approved the awards as inducements material to the new employees' employment in line with Nasdaq Rule 5635(c)(4).

Will KURA's inducement option grants immediately dilute existing shareholders?

The grants create potential future dilution if options are exercised, but immediate dilution does not occur until exercise. According to the company, the awards total 133,750 options and are subject to standard exercise and vesting conditions under the plan.